Want to see VOR full AI Analyst Report?

Vor Biopharma (VOR) Price & Analysis

959 Followers

VOR Stock Chart & Stats

$16.59

<$0.01(<0.01%)

At close: Jan 08 4:00 PM EST

$16.59

<$0.01(<0.01%)

Day’s Range― - ―

52-Week Range$6.50 - $65.80

Previous CloseN/A

Volume424.02K

Average Volume (3M)939.87K

Market Cap

$996.48M

Enterprise Value-$63.99M

Total Cash (Recent Filing)$491.52M

Total Debt (Recent Filing)$2.94M

Price to Earnings (P/E)―

Beta4.62

Next Earnings

Aug 06, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-575.83

Shares Outstanding54,185,880

10 Day Avg. Volume1,134,647

30 Day Avg. Volume939,867

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.79

Price to Sales (P/S)0.00

P/FCF Ratio-0.90

Enterprise Value/Market Cap-0.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit2.29K

Enterprise Value/Ebitda-0.14

Forecast

1Y Price Target

$29.75

Price Target Upside79.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-5.71

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Absolute LeverageVery low reported debt relative to assets materially reduces near-term interest and refinancing pressure versus peers. This durable capital-structure characteristic preserves optionality for R&D and partnering decisions, lowering bankruptcy risk and supporting multi‑period clinical investment flexibility.

Mechanism Validation Via Collaborator ApprovalA collaborator’s conditional approval for a BAFF/APRIL-targeting therapy validates the underlying biology and commercial potential of this mechanism. That external regulatory success de-risks Vor’s related programs, supports clinical strategy and partner interest, and strengthens the long-term scientific rationale for its HSC pairing approach.

Strengthened Governance And OversightRecent shareholder approvals of directors, an updated equity incentive plan, and Ernst & Young as auditor enhance governance, alignment and financial reporting credibility. Durable governance improvements improve access to capital, oversight of clinical spend, and investor confidence across funding cycles.

Bears Say

Pre-revenue With Widening LossesThe company remains pre-commercial with no revenue and materially widening net losses over recent periods. This persistent lack of operational income means long-term viability depends on external funding and successful clinical outcomes, increasing execution and dilution risk for ongoing multi‑year development programs.

Persistent Heavy Cash BurnSustained negative operating and free cash flow (TTM FCF ≈ -$151M) indicates cash consumption outpacing available resources. Durable operations will require recurring financing or partnerships, which can dilute shareholders and redirect management focus from science to capital raises, raising funding and execution risk over the next several quarters.

Negative Shareholders' EquityThe shift to negative equity reflects accumulated losses and weakens the balance sheet buffer. Negative equity constrains financial flexibility, limits secured financing options, and elevates probability of dilutive capital raises or restrictive financing terms—structural constraints for sustaining long‑duration clinical programs.

Vor Biopharma News

Vor Bio announces China NMPA approval for telitacicept

Vor Bio (VOR) and RemeGen announced that China’s National Medicinal Products Administration, or NMPA, has conditionally approved telitacicept...

24d ago

VOR

Vor Biopharma shareholders back directors and governance measures

The latest update is out from Vor Biopharma ( ($VOR) ). At its 2026 Annual Meeting, Vor Biopharma...

20d ago

VOR

Vor Bio gains boost from telitacicept IgA nephropathy approval

The latest announcement is out from Vor Biopharma ( ($VOR) ). Vor Bio and its collaborator RemeGen Co.,...

24d ago

VOR

Vor Biopharma’s Phase 3 Sjögren’s Trial Puts Telitacicept on Investors’ Radar

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. The phase 3 study called “A...

28d ago

VOR

Vor Biopharma: Buy Rating Reiterated on Strong Telitacicept Validation and Autoimmune Growth Runway; $31 Price Target Unchanged

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Vor Biopharma, retaining the price target of...

2M ago

VOR

Vor Bio price target raised to $18 from $15 at Wedbush

Wedbush analyst Martin Fan raised the firm’s price target on Vor Bio (VOR) to $18 from $15 and...

2M ago

VOR

Vor Biopharma Advances Phase 3 Telitacicept Trial in Myasthenia Gravis, Keeping Investor Focus High

Vor Biopharma, Inc. ($VOR) announced an update on their ongoing clinical study. Vor Biopharma, Inc. is running a...

2M ago

VOR

Vor Bio files to sell 5.34M shares of common stock for holders

16:13 EDT Vor Bio (VOR) files to sell 5.34M shares of common stock for holders Published first on...

2M ago

VOR

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

Insiders have been trading these 5 stocks: (($CLNN)), (($LOVE)), (($HDB)), (($STT)) and (($VOR)). Here is a breakdown of...

2M ago

HDB

STT

Bj’s, Atlas, Academy, Vor, Global-e: Insider Shakeup

Insiders have been trading these 5 stocks: (($BJ)), (($ATLX)), (($ASO)), (($VOR)) and (($GLBE)). Here is a breakdown of...

2M ago

ASO

Vor Bio price target lowered to $31 from $32 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a...

3M ago

VOR

Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up

Insiders have been trading these 5 stocks: (($IL:ESLT)), (($VOR)), (($GLBE)), (($SG)) and (($IMVT)). Here is a breakdown of...

3M ago

VOR

Vor Bio price target raised to $15 from $9 at Wedbush

Wedbush raised the firm’s price target on Vor Bio (VOR) to $15 from $9 and keeps a Neutral...

3M ago

VOR

Vor Bio price target lowered to $40 from $55 at Stifel

Stifel lowered the firm’s price target on Vor Bio (VOR) to $40 from $55 and keeps a Buy...

3M ago

VOR

VOR FAQ

What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $6.50 and its highest was $65.80 in the past 12 months.

What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $996.48M.

When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.

How were Vor Biopharma, Inc.’s earnings last quarter?

Vor Biopharma, Inc. released its earnings results on May 07, 2026. The company reported -$5.11 earnings per share for the quarter, missing the consensus estimate of -$0.781 by -$4.329.

Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.7.

How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 54,185,880 shares outstanding.

What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Vor Biopharma, Inc. reported an EPS of -$5.11 in its last earnings report, missing expectations of -$0.781. Following the earnings report the stock price went up 1.132%.

Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Vor Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

87.31%

Trailing 12-Months

Asset Growth

363.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vor Biopharma, Inc.

Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$29.75

▲(79.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","13":"$13","23":"$23","33":"$33","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,13,23,33,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.57,16.526153846153846,18.482307692307693,20.43846153846154,22.394615384615385,24.35076923076923,26.306923076923077,28.263076923076923,30.21923076923077,32.175384615384615,34.13153846153846,36.08769230769231,38.043846153846154,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.57,15.737692307692308,16.905384615384616,18.073076923076922,19.24076923076923,20.408461538461538,21.576153846153844,22.743846153846153,23.911538461538463,25.07923076923077,26.246923076923075,27.414615384615384,28.58230769230769,{"y":29.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.57,14.833846153846155,15.097692307692308,15.361538461538462,15.625384615384615,15.88923076923077,16.153076923076924,16.416923076923077,16.68076923076923,16.944615384615386,17.20846153846154,17.472307692307695,17.736153846153847,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.39,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >